With the approval of oral Wegovy making headlines in the new year, it was timely to catch up with Chris on this and many other exciting developments in the realm of GLP-1s. In our main discussion, Chris talks about the immediate impact of oral Wegovy and some small but important differences from its injectable predecessors. He also gets into the application of GLP-1s outside of weight loss, the promise of new agents currently in development, the impact of GLP-1s in corrections healthcare and addresses growing concerns over safety, side-effects, and availability.

For Into the Clinic, Chris shares some important updates involving gonorrhea treatments, functional seizure guidelines, ADA diabetes guidelines, and the GOLD COPD guidelines.

And in our Trivia Capsule segment, we look back at some spectacular failures in the history of weight  ...